Stemline Therapeutics, Inc. [STML] To Ring The NASDAQ Stock Market Opening Bell In Celebration Of Initial Public Offering

ADVISORY, Feb. 8, 2013 (GLOBE NEWSWIRE) --

What:

Stemline Therapeutics, Inc. [STML], a clinical stage biopharmaceutical company developing novel oncology therapeutics that target both cancer stem cells (CSCs) as well as the tumor bulk, will visit the NASDAQ MarketSite in Times Square in celebration of its initial public offering (IPO), which occurred on January 29 on The NASDAQ Stock Market.

In honor of the occasion, Ivan Bergstein M.D., CEO will ring the Opening Bell.

Where:

NASDAQ MarketSite – 4 Times Square – 43 rd & Broadway – Broadcast Studio

When:

Monday, February 11, 2013 – 9:15 a.m. to 9:30 a.m. ET

Contact:

Mark Jacobson (646) 502-2307 Mjacobson@stemline.com

NASDAQ MarketSite: Jen Knapp (212) 401-8916 Jennifer.knapp@nasdaqomx.com

Feed Information:

Fiber Line (Encompass Waterfront): 4463

Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC 3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK

Facebook and Twitter:

For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at: http://www.facebook.com/NASDAQ .                  

For news tweets, please visit our Twitter page at: http://twitter.com/nasdaqomx .

Webcast:

A live webcast of the NASDAQ Opening Bell will be available at: http://www.nasdaq.com/about/marketsitetowervideo.asx .

Photos:

To obtain a hi-resolution photograph of the Market Open, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market open of your choice.                              

About Stemline Therapeutics, Inc. [STML]:

Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company developing novel oncology therapeutics that target both cancer stem cells (CSCs) as well as the tumor bulk. Among Stemline's drug candidates are SL-401 and SL-701, both of which have demonstrated clinical activity, including durable complete responses (CRs), and an overall survival (OS) benefit versus historical controls in Phase 1/2 studies of advanced cancer patients. For more information about Stemline Therapeutics, visit www.stemline.com.

About NASDAQ OMX Group:

The inventor of the electronic exchange, The NASDAQ OMX Group, Inc., fuels economies and provides transformative technologies for the entire lifecycle of a trade - from risk management to trade to surveillance to clearing. In the U.S. and Europe, we own and operate 23 markets, 3 clearinghouses and 5 central securities depositories supporting equities, options, fixed income, derivatives, commodities, futures and structured products. Able to process more than 1 million messages per second at sub-40 microsecond speeds with 99.99+% uptime, our technology drives more than 70 marketplaces in 50 developed and emerging countries into the future, powering 1 in 10 of the world's securities transactions. Our award-winning data products and worldwide indexes are the benchmarks in the financial industry. Home to approximately 3,400 listed companies worth $6 trillion in market cap whose innovations shape our world, we give the ideas of tomorrow access to capital today. Welcome to where the world takes a big leap forward, daily. Welcome to the NASDAQ OMX Century. To learn more, visit www.nasdaqomx.com . Follow us on Facebook ( www.facebook.com/NASDAQ ) and Twitter ( www.twitter.com/nasdaqomx ). (Symbol: NDAQ and member of S&P 500)

-NDAQA-

If you liked this article you might like

Watch: Meet This New ETF Tracking Blockchain Related Companies Like IBM

Watch: Meet This New ETF Tracking Blockchain Related Companies Like IBM

Closing Bell: LIVE MARKETS BLOG

Closing Bell: LIVE MARKETS BLOG

Nasdaq, Singapore's SGX Announce Agreement Allowing Collaborative Listings

Nasdaq, Singapore's SGX Announce Agreement Allowing Collaborative Listings

Walt Disney, Tiffany, NASDAQ, Mazor Robotics: 'Mad Money' Lightning Round

Walt Disney, Tiffany, NASDAQ, Mazor Robotics: 'Mad Money' Lightning Round

A Ferocious Rotation: Cramer's 'Mad Money' Recap (Friday 6/9/17)

A Ferocious Rotation: Cramer's 'Mad Money' Recap (Friday 6/9/17)